Sara Calattini

Prognostic value of baseline circulating methylated nucleosomes in treatment-intent cohorts of non-small cell lung cancer

Marie Piecyk, Emmanuel Grolleau, Sara Calattini, Aurore Carrot et autres

fr, us (code pays fourni par la source)

Prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer

Marie Piecyk, Emmanuel Grolleau, Sara Calattini, Aurore Carrot et autres

fr, us (code pays fourni par la source)

1738eTiP IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy (domvanalimab + zimberelimab) in patients with advanced rare cancers: The neuroendocrine tumors cohort

Laurence Gérard, Julien Hadoux, S. Hescot, C. Do Cao et autres

fr, ca, in (code pays fourni par la source)

Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study

Benoît You, S. Couraud, Philippe Céruse, Lionel Badet et autres

fr, us, in, ch (code pays fourni par la source)

IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers-The B3 Thymomas and Thymic Carcinomas Cohort

M. Duruisseaux, Benjamin Besse, Nicolas Girard, Éric Dansin et autres

IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Anaplastic Thyroid Carcinomas Cohort.

Hélène Lasolle, Julien Hadoux, S. Hescot, Arnaud Jannin et autres

fr (code pays fourni par la source)

IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Peritoneal Mesotheliomas Cohort.

Julien Péron, Valérie Boige, Pascale Mariani, Clarisse Eveno et autres

fr (code pays fourni par la source)

IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.

M. Duruisseaux, Benjamin Besse, Nicolas Girard, Éric Dansin et autres

fr (code pays fourni par la source)

IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Gestational Trophoblastic Tumors Cohort.

Benoît You, Alexandra Léary, Mathieu Jamelot, Pauline Parent et autres

fr (code pays fourni par la source)

1333P Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study

L.F-G. Payen, S. Couraud, Aurore Carrot, Gaëlle Lescuyer et autres

fr, in (code pays fourni par la source)

136P Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study

Byungjun You, Philippe Céruse, S. Couraud, M. Duruisseaux et autres

fr, in (code pays fourni par la source)

235P Baseline values of circulating nucleosomes in non-small lung cancer (NSCLC): ONCOPRO_LUNG study

S. Couraud, Aurore Carrot, Gaëlle Lescuyer, Maja Piecyk et autres

fr (code pays fourni par la source)